[mo_oauth_login]
Summary report
CENTRALPHARMA COMMUNICATIONS OÜ
Date of report 17.05.2025
CENTRALPHARMA COMMUNICATIONS OÜ
10640025 -
Registered
Founded in
28.01.2000
Fixed capital
2,556 €
Former names
- Osaühing Tsentraalfarmaatsia
VAT
EE100629860
(start 01.08.2000)
| start | end |
|---|---|
| 01.08.2000 | - |
keywords
- esindused
- rahvusvahelised organisatsioonid
- riik ja ühiskond
- ühingud
- ärinõustamine
CENTRALPHARMA COMMUNICATIONS OÜ
Scores and ratings
Reputation score
1930
What is Reputation score?
Credit Score
Trustworthy
0.01
Credit score today
Trustworthy
0.01
2001
year
Open the reports you want to print
Employees and salaries
CENTRALPHARMA COMMUNICATIONS OÜ
Number of employees and estimated average salaries?
| 2024 II | 2024 III | 2024 IV | 2025 I | |
| Number of employees | ...... | ...... | ...... | ...... |
| Average gross salary | ...... | ...... | ...... | ...... |
CENTRALPHARMA COMMUNICATIONS OÜ
Employee taxes and performance analysis?
| Quarter | Labor taxes paid | Number of employees | Turnover Per Employee | Profit per employee |
|---|---|---|---|---|
| 2025 I | ...... | ...... | ...... | ...... |
| 2024 IV | ...... | ...... | ...... | ...... |
| 2024 III | ...... | ...... | ...... | ...... |
| 2024 II | ...... | ...... | ...... | ...... |
| 2024 I | ...... | ...... | ...... | ...... |
| 2023 IV | ...... | ...... | ...... | ...... |
| 2023 III | ...... | ...... | ...... | ...... |
| 2023 II | ...... | ...... | ...... | ...... |
| 2023 I | ...... | ...... | ...... | ...... |
| 2022 IV | ...... | ...... | ...... | ...... |
| 2022 III | ...... | ...... | ...... | ...... |
| 2022 II | ...... | ...... | ...... | ...... |
| 2022 I | ...... | ...... | ...... | ...... |
| 2021 IV | ...... | ...... | ...... | ...... |
| 2021 III | ...... | ...... | ...... | ...... |
| 2021 II | ...... | ...... | ...... | ...... |
| 2021 I | ...... | ...... | ...... | ...... |
| 2020 IV | ...... | ...... | ...... | ...... |
| 2020 III | ...... | ...... | ...... | ...... |
| 2020 II | ...... | ...... | ...... | ...... |
| 2020 I | ...... | ...... | ...... | ...... |
| 2019 IV | ...... | ...... | ...... | ...... |
| 2019 III | ...... | ...... | ...... | ...... |
| 2019 II | ...... | ...... | ...... | ...... |
| 2019 I | ...... | ...... | ...... | ...... |
| 2018 IV | ...... | ...... | ...... | ...... |
| 2018 III | ...... | ...... | ...... | ...... |
| 2018 II | ...... | ...... | ...... | ...... |
| 2018 I | ...... | ...... | ...... | ...... |
| 2017 IV | ...... | ...... | ...... | ...... |
| 2017 III | ...... | ...... | ...... | ...... |
| 2017 II | ...... | ...... | ...... | ...... |
| 2017 I | ...... | ...... | ...... | ...... |
| 2016 IV | ...... | ...... | ...... | ...... |
| 2016 III | ...... | ...... | ...... | ...... |
| 2016 II | ...... | ...... | ...... | ...... |
| 2016 I | ...... | ...... | ...... | ...... |
| 2015 IV | ...... | ...... | ...... | ...... |
| 2015 III | ...... | ...... | ...... | ...... |
| 2015 II | ...... | ...... | ...... | ...... |
| 2015 I | ...... | ...... | ...... | ...... |
Deciders and beneficiaries
CENTRALPHARMA COMMUNICATIONS OÜ
Decision-makers?
Former decision-makers
Relations:
2
Turnover 2025:
1 130 615 €
Employees:
6
Kadri Känd
★★★★
......
Credit Score: Trustworthy
Reputation score: 2500
Date of birth: ......
Active relations 2
39 followers
*
CENTRALPHARMA COMMUNICATIONS OÜ
Former decision-makers?
Relations:
2
Turnover 2025:
64 392 030 €
Employees:
313
Rainar Aamisepp
★★★★
......
Credit Score: Borderline
Reputation score: 21970
Date of birth: ......
Active relations 2
126 followers
CENTRALPHARMA COMMUNICATIONS OÜ
History of right of representation?
Field
Administrative Activities
Business age
25y
Beneficial country:
Estonia
2000
2004
2007
2011
2014
2018
2021
2025
2000
2002
2005
2007
2009
2011
2014
2016
2018
2020
2023
2025
CENTRALPHARMA COMMUNICATIONS OÜ
Owners?
Former owners
Beneficiaries
Volumes and values of beneficiaries' assets
Net asset value of the beneficiary
... €
Value of beneficiary companies using the income method
... €
Analytically identified company holdings and asset volumes
Finances and assets
CENTRALPHARMA COMMUNICATIONS OÜ ...
Goodwill| EUR | 2023 | 2024 | 2025 | Trend |
| Goodwill | ...... | ...... | ...... | |
| Goodwill | ...... | ...... | ...... |
CENTRALPHARMA COMMUNICATIONS OÜ
Taxes paid and estimated average salaries| 2022 | 2023 | 2024 | 2025 | |
| National taxes | ...... | ...... | ...... | ...... |
| Labor taxes | ...... | ...... | ...... | ...... |
| Average gross salary | ...... | ...... | ...... | ...... |
CENTRALPHARMA COMMUNICATIONS OÜ
Quarterly indicators| Quarter | Turnover | Taxed turnover | Labour productivity | Labour productivity | Employees | National taxes | Labor taxes |
|---|---|---|---|---|---|---|---|
| 2025 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2024 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2024 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2024 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2024 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2016 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2016 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2016 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2016 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2015 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2015 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2015 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2015 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
CENTRALPHARMA COMMUNICATIONS OÜ
Sales revenue by business arearevenue
| Field of activity | EMTAK code | Sales revenue (2023) | Sales revenue % |
| Real Estate Rental | 68201 | 26 157 € | 2,49 |
| Business advice | 70221 | 1 023 458 € | 97,51 |
CENTRALPHARMA COMMUNICATIONS OÜ ...
Sales revenue by country| Turnover EUR | 2023 | 2024 prognosis | 2025 prognosis | Trend |
| Total sales | ...... | ...... | ...... | |
| Estonia | ...... | ...... | ...... | |
| Ascension Island | ...... | ...... | ...... | |
| Austria | ...... | ...... | ...... | |
| Czechia | ...... | ...... | ...... | |
| Denmark | ...... | ...... | ...... | |
| Finland | ...... | ...... | ...... | |
| France | ...... | ...... | ...... | |
| Germany | ...... | ...... | ...... | |
| Greece | ...... | ...... | ...... | |
| Hungary | ...... | ...... | ...... | |
| Ireland | ...... | ...... | ...... | |
| Israel | ...... | ...... | ...... | |
| Italy | ...... | ...... | ...... | |
| Latvia | ...... | ...... | ...... | |
| Leed | ...... | ...... | ...... | |
| Lithuania | ...... | ...... | ...... | |
| Netherlands | ...... | ...... | ...... | |
| Netherlands Antilles | ...... | ...... | ...... | |
| Norway | ...... | ...... | ...... | |
| Poland | ...... | ...... | ...... | |
| Slovenia | ...... | ...... | ...... | |
| Spain | ...... | ...... | ...... | |
| Sweden | ...... | ...... | ...... | |
| Switzerland | ...... | ...... | ...... | |
| United Kingdom of Great Britain and Northern Ireland | ...... | ...... | ...... | |
| United States of America | ...... | ...... | ...... | |
| Total exports | ...... | ...... | ...... |
CENTRALPHARMA COMMUNICATIONS OÜ ...
Financial indicators and prognosis| Financial indicators | 2023 | 2024 Prognosis | 2025 Prognosis |
Trend |
| TURNOVER | ...... | ...... | ...... | |
| Estonia | ...... | ...... | ...... | |
| Other countries | ...... | ...... | ...... | |
| INTEREST INCOME | ...... | ...... | ...... | |
| OTHER BUSINESS INCOME | ...... | ...... | ...... | |
| TURNOVER IN RELATED COMPANY | ...... | ...... | ...... | |
| AVERAGE MONTHLY TURNOVER | ...... | ...... | ...... | |
| Available credit (credit limit) | ...... | ...... | ...... | |
| Settlement dates | ...... | ...... | ...... | |
| RECEIVED GRANTS € | ...... | ...... | ...... | |
| TENDERS WON € | ...... | ...... | ...... | |
| ASSETS | ...... | ...... | ...... | |
| Current assets | ...... | ...... | ...... | |
| Fixed assets | ...... | ...... | ...... | |
| LIABILITIES | ...... | ...... | ...... | |
| Short-term liabilities | ...... | ...... | ...... | |
| Long-term liabilities | ...... | ...... | ...... | |
| EQUITY | ...... | ...... | ...... | |
| Share-(equity capital) | ...... | ...... | ...... | |
| Retained profits | ...... | ...... | ...... | |
| Net profit | ...... | ...... | ...... | |
| NET WORKING CAPITAL | ...... | ...... | ...... | |
| NUMBER OF EMPLOYEES | ...... | ...... | ...... |
CENTRALPHARMA COMMUNICATIONS OÜ ...
Financial raiting: "VERY GOOD" (2025 prognosis)| Multipliers and income levels | 2024 prognosis | 2025 prognosis |
Trend |
| LIQUIDITY | ...... | ...... | |
| Net Working capital | ...... | ...... | |
| Short-term debt coverage ratio (X) | ...... | ...... | |
| EFFECTIVENESS | ...... | ...... | |
| Debt to assets ratio (X) | ...... | ...... | |
| Capitalisation multiplier (X) | ...... | ...... | |
| USE OF LOAN CAPITAL | ...... | ...... | |
| Turnover ratio of fixed assets (X) | ...... | ...... | |
| PROFITABILITY | ...... | ...... | |
| Sales revenues (%) | ...... | ...... | |
| Total asset revenues (%) | ...... | ...... | |
| Equity revenues (%) | ...... | ...... |
2025 prognosis
LIQUIDITY
?
Net Working capital
...
Short-term debt coverage ratio
...
USE OF LOAN CAPITAL
?
Turnover ratio of fixed assets (X)
...
EFFECTIVENESS
?
Debt to assets ratio (X)
...
Capitalisation multiplier (X)
...
PROFITABILITY
?
Sales revenues (%)
...
Total asset revenues (%)
...
Equity revenues (%)
...
Unsatisfactory
1
2
3
4
5
Very good
CENTRALPHARMA COMMUNICATIONS OÜ
Real estate as of 17.05.2025Active and unactive real estate
P......
P......
J......
L......
L......
CENTRALPHARMA COMMUNICATIONS OÜ
Annual reports| Year | Period | Submitted | Report PDF |
|---|---|---|---|
| 2023 | 01.01.2023–31.12.2023 | 21.06.2024 | ...... |
| 2022 | 01.01.2022–31.12.2022 | 20.06.2023 | ...... |
| 2021 | 01.01.2021–31.12.2021 | 29.06.2022 | ...... |
| 2020 | 01.01.2020–31.12.2020 | 21.09.2021 | ...... |
| 2019 | 01.01.2019–31.12.2019 | 13.08.2020 | ...... |
| 2018 | 01.01.2018–31.12.2018 | 08.07.2019 | ...... |
| 2017 | 01.01.2017–31.12.2017 | 29.08.2018 | ...... |
| 2016 | 01.01.2016–31.12.2016 | 30.06.2017 | ...... |
| 2015 | 01.01.2015–31.12.2015 | 01.07.2016 | ...... |
| 2014 | 01.01.2014–31.12.2014 | 30.06.2015 | ...... |
| 2013 | 01.01.2013–31.12.2013 | 29.04.2014 | ...... |
| 2012 | 01.01.2012–31.12.2012 | 17.06.2013 | ...... |
| 2011 | 01.01.2011–31.12.2011 | 03.07.2012 | ...... |
| 2010 | 01.01.2010–31.12.2010 | 29.06.2011 | ...... |
| 2009 | 01.01.2009–31.12.2009 | 27.05.2010 | ...... |
| 2008 | 01.01.2008–31.12.2008 | 01.07.2009 | ...... |
| 2007 | 01.01.2007–31.12.2007 | 27.06.2008 | ...... |
| 2006 | 01.01.2006–31.12.2006 | 26.06.2007 | ...... |
| 2005 | 01.01.2005–31.12.2005 | 30.06.2006 | ...... |
| 2004 | 01.01.2004–31.12.2004 | 29.06.2005 | ...... |
| 2003 | 01.01.2003–31.12.2003 | 30.06.2004 | ...... |
| 2002 | 01.01.2002–31.12.2002 | 30.06.2003 | ...... |
| 2001 | 01.01.2001–31.12.2001 | 01.07.2002 | ...... |
| 2000 | 01.01.2000–31.12.2000 | 06.07.2001 | ...... |
Liabilities and debts
CENTRALPHARMA COMMUNICATIONS OÜ
Credit score history and prognosisRecommended credit limit
... €
Recommended payment term
......
Business risk classes:
Trustworthy Neutral
Borderline
Problematic
Risky
CENTRALPHARMA COMMUNICATIONS OÜ
Reports and assets-liabilities overview 17.05.2025?
Annual reports:
......
Annual reports: ......
Tax declarations:......
Assets to cover liabilities (short-term)
Assets: ...... €1 EURO of assets to cover short-term debt obligations: ...... €
Liabilities: ...... €Net Working capital: ...... €
CENTRALPHARMA COMMUNICATIONS OÜ
Claims history?
1 month
6 months
Year
5 years
MAX
1 month
6 months
Year
5 years
MAX
Debt claims as of ......
Total debt claims: ...... €
Latest events
| ...... | ...... |
CENTRALPHARMA COMMUNICATIONS OÜ
Income (turnover) and expenditure (taxes paid)?
| Quarter | Turnover | Taxed turnover | National taxes paid | Labor taxes paid | Number of employees |
|---|---|---|---|---|---|
| 2025 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2024 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2024 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2024 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2024 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2016 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2016 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2016 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2016 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2015 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2015 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2015 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2015 I | * ...... € | ...... € | ...... € | ...... € | ...... |
CENTRALPHARMA COMMUNICATIONS OÜ
Bailiff's enforcement proceedings as of 17.05.2025?
Bailiff's enforcement proceedings MISSING
CENTRALPHARMA COMMUNICATIONS OÜ
Regulations of the Payment Order Department as of 17.05.2025?
Regulations of the Payment Order Department MISSING
CENTRALPHARMA COMMUNICATIONS OÜ
Court orders in the register as of 17.05.2025?
Puuduste kõrvaldamise määrus
22.05.2023
Regulation number: Ä 10047070 / M3
Regulation status has entered into force: 22.05.2023
Regulation status: Allkirjastatud
CENTRALPHARMA COMMUNICATIONS OÜ
Decisions of the Consumer Disputes Committee as of 17.05.2025?
Consumer disputes MISSING
CENTRALPHARMA COMMUNICATIONS OÜ
Court hearings as of 17.05.2025?
Court hearings MISSING
CENTRALPHARMA COMMUNICATIONS OÜ
Rulings as of 17.05.2025?
Court settlemets MISSING
CENTRALPHARMA COMMUNICATIONS OÜ
Notices and announcements as of 17.05.2025?
Notice of division of a company
20.06.2023
Äriühingu jagunemise teade
Avaldamise algus: 20.06.2023
Avaldamise lõpp: tähtajatu
Avaldamise lõpp: tähtajatu
OÜ CentralPharma Communications (registrikood 10640025) avaldab teadaande äriseadustiku (ÄS) § 447 lõike 2¹ alusel.
Ühing teatab jagunemisest. Jagunemisel osalesid OÜ CentralPharma Communications (registrikood 10640025) ja Impresa OÜ (registrikood: 16761965), asukoht: Harju maakond, Tallinn, Haabersti linnaosa, Roostiku tn 29, 13516.
Äriühingute võlausaldajatel palume esitada oma nõuded tagatise saamiseks kuue kuu jooksul käesoleva teate avaldamisest (ÄS § 447 lg 21). centralpharma@centralpharma.ee
Ühing teatab jagunemisest. Jagunemisel osalesid OÜ CentralPharma Communications (registrikood 10640025) ja Impresa OÜ (registrikood: 16761965), asukoht: Harju maakond, Tallinn, Haabersti linnaosa, Roostiku tn 29, 13516.
Äriühingute võlausaldajatel palume esitada oma nõuded tagatise saamiseks kuue kuu jooksul käesoleva teate avaldamisest (ÄS § 447 lg 21). centralpharma@centralpharma.ee
Ärinimed
OÜ CentralPharma Communications, kehtetud ärinimed: Osaühing Tsentraalfarmaatsia.
OÜ CentralPharma Communications
Haabersti linnaosa, Tallinn, Harju maakond, Lesta tn 26-11
Telefon: +372 6015740
E-post: centralpharma@centralpharma.ee
Haabersti linnaosa, Tallinn, Harju maakond, Lesta tn 26-11
Telefon: +372 6015740
E-post: centralpharma@centralpharma.ee
Teadaande avaldaja kontaktandmed:
KADRI KÄND
KADRI KÄND
Teadaande number 2086773
Marketing
Business network
CENTRALPHARMA COMMUNICATIONS OÜ
Business networkCREDIT RISK CLASSES
Deleted
Trustworthy
Neutral
Borderline
Problematic
Risky
Historical connection
Active connection
amount of turnover
amount of debt
Extension of networks
The network is visible with reduced links
Expand threads if desired
Sign in
To expand your connections, log in to the "Networks" environment
Beneficiaries network
CENTRALPHARMA COMMUNICATIONS OÜ
Networks - Beneficiaries
The network is visible with reduced links
Expand threads if desired
Sign in
To expand your connections, log in to the "Networks" environment
Monitoring events
Filter
Dropdown
Dropdown
Neutral
Positive
Negative
No monitoring events found.
Failed to load monitoring events.